A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial of the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date5/20/204/3/23

Funding

  • Syneos Health LLC: $16,818.00